Tyra Biosciences and BCAN Launch UTUC Awareness Day, Advance Dabogratinib Phase 2 Study
Tyra Biosciences and the Bladder Cancer Advocacy Network have designated May 21 as Upper Tract Urothelial Cancer Awareness Day to highlight the rarity of UTUC and high FGFR3 mutation rates. Tyra is dosing patients with oral dabogratinib in its Phase 2 SURF303 trial as a kidney-sparing approach for low-grade UTUC.
1. Establishment of UTUC Awareness Day
Tyra Biosciences and the Bladder Cancer Advocacy Network designated May 21 as Upper Tract Urothelial Cancer Awareness Day to spotlight the rare disease and the high prevalence of FGFR3 alterations in kidney and ureter cancers.
2. Significant Unmet Needs in UTUC
UTUC patients currently rely on endoscopic ablation or nephroureterectomy, often resulting in kidney removal and long-term complications, with no established systemic standard of care for FGFR3-driven low-grade cases.
3. Ongoing Dabogratinib Phase 2 Trial
TYRA is dosing patients with oral dabogratinib in the Phase 2 SURF303 study, aiming to offer a first-in-class, kidney-sparing FGFR3-selective treatment for low-grade UTUC with a differentiated tolerability profile.